Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Attention Deficit Disorder with Hyperactivity | 196 | 2024 | 3708 | 10.760 |
Why?
|
Central Nervous System Stimulants | 64 | 2023 | 1177 | 5.930 |
Why?
|
Methylphenidate | 47 | 2023 | 488 | 5.880 |
Why?
|
Propylamines | 33 | 2011 | 161 | 3.530 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 14 | 2012 | 415 | 2.300 |
Why?
|
Adrenergic Uptake Inhibitors | 18 | 2010 | 186 | 2.040 |
Why?
|
Amphetamines | 16 | 2008 | 143 | 1.680 |
Why?
|
Adolescent Psychiatry | 2 | 2024 | 157 | 1.620 |
Why?
|
Child Psychiatry | 2 | 2024 | 228 | 1.490 |
Why?
|
Delayed-Action Preparations | 38 | 2018 | 962 | 1.400 |
Why?
|
Psychiatric Status Rating Scales | 47 | 2018 | 6019 | 1.360 |
Why?
|
Euphoria | 2 | 2018 | 65 | 1.200 |
Why?
|
Amphetamine | 8 | 2013 | 224 | 1.180 |
Why?
|
Cocaine | 7 | 2012 | 958 | 1.010 |
Why?
|
Naltrexone | 2 | 2018 | 317 | 1.000 |
Why?
|
Veterans | 4 | 2020 | 2649 | 0.850 |
Why?
|
Double-Blind Method | 56 | 2024 | 12341 | 0.830 |
Why?
|
Dopamine Uptake Inhibitors | 7 | 2019 | 297 | 0.820 |
Why?
|
Stress Disorders, Post-Traumatic | 10 | 2020 | 4575 | 0.800 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 9 | 2012 | 306 | 0.790 |
Why?
|
Horses | 2 | 2020 | 300 | 0.730 |
Why?
|
Equine-Assisted Therapy | 1 | 2020 | 3 | 0.710 |
Why?
|
Adolescent | 114 | 2024 | 88326 | 0.700 |
Why?
|
Antidepressive Agents, Tricyclic | 6 | 2008 | 432 | 0.690 |
Why?
|
Substance-Related Disorders | 16 | 2023 | 4420 | 0.690 |
Why?
|
Growth | 3 | 2007 | 365 | 0.680 |
Why?
|
Nicotine | 9 | 2023 | 680 | 0.640 |
Why?
|
Body Height | 8 | 2010 | 1570 | 0.640 |
Why?
|
Music Therapy | 1 | 2020 | 110 | 0.610 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 27 | 2020 | 1988 | 0.600 |
Why?
|
Mind-Body Therapies | 1 | 2020 | 279 | 0.560 |
Why?
|
Narcotic Antagonists | 3 | 2018 | 585 | 0.550 |
Why?
|
Drug Administration Schedule | 22 | 2018 | 4853 | 0.550 |
Why?
|
Child | 98 | 2024 | 80158 | 0.550 |
Why?
|
Body Weight | 11 | 2020 | 4618 | 0.510 |
Why?
|
Comorbidity | 32 | 2024 | 10508 | 0.510 |
Why?
|
Osmosis | 4 | 2016 | 103 | 0.490 |
Why?
|
Corpus Striatum | 6 | 2012 | 1235 | 0.480 |
Why?
|
Adult | 121 | 2024 | 221210 | 0.480 |
Why?
|
Male | 173 | 2024 | 360846 | 0.480 |
Why?
|
Conduct Disorder | 6 | 2014 | 245 | 0.470 |
Why?
|
Female | 180 | 2024 | 392705 | 0.470 |
Why?
|
Dose-Response Relationship, Drug | 24 | 2019 | 10766 | 0.460 |
Why?
|
Radioligand Assay | 2 | 2011 | 366 | 0.450 |
Why?
|
Positron-Emission Tomography | 7 | 2011 | 6484 | 0.450 |
Why?
|
Bipolar Disorder | 22 | 2015 | 5092 | 0.450 |
Why?
|
Humans | 222 | 2024 | 761596 | 0.440 |
Why?
|
Adrenergic alpha-Agonists | 3 | 2010 | 177 | 0.410 |
Why?
|
Students | 2 | 2020 | 1741 | 0.410 |
Why?
|
Tic Disorders | 2 | 2024 | 136 | 0.400 |
Why?
|
Psychiatry | 2 | 2024 | 1693 | 0.390 |
Why?
|
Bupropion | 7 | 2007 | 304 | 0.380 |
Why?
|
Program Evaluation | 1 | 2020 | 2495 | 0.370 |
Why?
|
Memory, Short-Term | 5 | 2021 | 982 | 0.370 |
Why?
|
Mood Disorders | 9 | 2010 | 1127 | 0.370 |
Why?
|
Raclopride | 1 | 2010 | 101 | 0.360 |
Why?
|
Guanfacine | 3 | 2009 | 51 | 0.360 |
Why?
|
Brain | 16 | 2018 | 27121 | 0.360 |
Why?
|
Executive Function | 8 | 2018 | 1392 | 0.360 |
Why?
|
Patient Satisfaction | 2 | 2020 | 3462 | 0.350 |
Why?
|
Emotional Intelligence | 1 | 2011 | 135 | 0.350 |
Why?
|
Treatment Outcome | 54 | 2020 | 64685 | 0.340 |
Why?
|
Cross-Over Studies | 10 | 2024 | 2079 | 0.340 |
Why?
|
Depressive Disorder | 8 | 2014 | 3728 | 0.330 |
Why?
|
Health Services | 1 | 2014 | 752 | 0.330 |
Why?
|
Monoamine Oxidase Inhibitors | 3 | 2004 | 156 | 0.330 |
Why?
|
Health Status Indicators | 1 | 2014 | 970 | 0.320 |
Why?
|
Psychotic Disorders | 6 | 2024 | 3223 | 0.320 |
Why?
|
Prenatal Exposure Delayed Effects | 6 | 2018 | 2518 | 0.310 |
Why?
|
Young Adult | 39 | 2024 | 59260 | 0.310 |
Why?
|
Neurobiology | 2 | 2023 | 137 | 0.310 |
Why?
|
Impulsive Behavior | 4 | 2018 | 346 | 0.300 |
Why?
|
Anxiety Disorders | 12 | 2023 | 2720 | 0.300 |
Why?
|
Social Control, Informal | 3 | 2013 | 44 | 0.300 |
Why?
|
Uterus | 3 | 2009 | 649 | 0.300 |
Why?
|
Antidepressive Agents | 10 | 2011 | 2897 | 0.290 |
Why?
|
Desipramine | 3 | 2008 | 182 | 0.290 |
Why?
|
Cholinesterase Inhibitors | 2 | 2006 | 242 | 0.290 |
Why?
|
Psychometrics | 13 | 2018 | 3065 | 0.290 |
Why?
|
Dopamine | 3 | 2012 | 1607 | 0.290 |
Why?
|
Referral and Consultation | 7 | 2020 | 3600 | 0.280 |
Why?
|
Benzhydryl Compounds | 3 | 2010 | 916 | 0.280 |
Why?
|
Severity of Illness Index | 26 | 2012 | 15843 | 0.270 |
Why?
|
Middle Aged | 59 | 2020 | 220921 | 0.270 |
Why?
|
Biogenic Monoamines | 2 | 2021 | 50 | 0.270 |
Why?
|
Galantamine | 1 | 2006 | 33 | 0.260 |
Why?
|
Neuropsychological Tests | 14 | 2014 | 7054 | 0.260 |
Why?
|
Emotions | 5 | 2020 | 2739 | 0.250 |
Why?
|
Telemedicine | 2 | 2021 | 3052 | 0.250 |
Why?
|
Obsessive-Compulsive Disorder | 3 | 2003 | 1491 | 0.240 |
Why?
|
Placebos | 9 | 2011 | 1667 | 0.240 |
Why?
|
Tourette Syndrome | 1 | 2007 | 395 | 0.230 |
Why?
|
Antidepressive Agents, Second-Generation | 3 | 2004 | 489 | 0.230 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2004 | 97 | 0.230 |
Why?
|
Mental Disorders | 10 | 2013 | 6845 | 0.230 |
Why?
|
Memory Disorders | 3 | 2018 | 1199 | 0.220 |
Why?
|
Pregnancy, Animal | 3 | 2009 | 124 | 0.220 |
Why?
|
Family Health | 4 | 2013 | 1257 | 0.220 |
Why?
|
Dextroamphetamine | 3 | 2011 | 134 | 0.220 |
Why?
|
Memantine | 2 | 2016 | 108 | 0.220 |
Why?
|
Quality of Life | 13 | 2020 | 13367 | 0.220 |
Why?
|
Diazepam | 1 | 2024 | 215 | 0.210 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 3769 | 0.210 |
Why?
|
Growth Disorders | 2 | 2010 | 655 | 0.210 |
Why?
|
Alleles | 3 | 2012 | 6864 | 0.210 |
Why?
|
Health Behavior | 1 | 2014 | 2644 | 0.210 |
Why?
|
Gyrus Cinguli | 3 | 2017 | 1115 | 0.210 |
Why?
|
Age Factors | 18 | 2017 | 18399 | 0.210 |
Why?
|
Minisatellite Repeats | 3 | 2012 | 163 | 0.210 |
Why?
|
Child Behavior Disorders | 3 | 2009 | 804 | 0.210 |
Why?
|
Life Style | 1 | 2014 | 3917 | 0.210 |
Why?
|
Administration, Oral | 8 | 2016 | 4021 | 0.210 |
Why?
|
Tomography, Emission-Computed | 1 | 2005 | 1122 | 0.200 |
Why?
|
Psychopharmacology | 1 | 2024 | 148 | 0.200 |
Why?
|
Nerve Fibers, Unmyelinated | 2 | 2013 | 98 | 0.200 |
Why?
|
Psychology | 1 | 2024 | 356 | 0.200 |
Why?
|
Self Report | 6 | 2020 | 3725 | 0.190 |
Why?
|
Matrix Metalloproteinases | 1 | 2004 | 393 | 0.190 |
Why?
|
Social Adjustment | 4 | 2013 | 632 | 0.190 |
Why?
|
Schizotypal Personality Disorder | 1 | 2023 | 290 | 0.190 |
Why?
|
Pilot Projects | 6 | 2020 | 8633 | 0.190 |
Why?
|
Teaching | 2 | 2006 | 1170 | 0.190 |
Why?
|
Cognition Disorders | 7 | 2018 | 3980 | 0.190 |
Why?
|
Chi-Square Distribution | 5 | 2010 | 3415 | 0.190 |
Why?
|
Alcoholism | 2 | 2002 | 1973 | 0.180 |
Why?
|
Saccharin | 1 | 2020 | 20 | 0.180 |
Why?
|
Animals, Newborn | 2 | 2017 | 2677 | 0.180 |
Why?
|
Siblings | 3 | 2015 | 825 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2013 | 3359 | 0.180 |
Why?
|
Sensory Receptor Cells | 1 | 2005 | 513 | 0.180 |
Why?
|
Aggression | 4 | 2014 | 750 | 0.170 |
Why?
|
Carbon Radioisotopes | 2 | 2011 | 561 | 0.170 |
Why?
|
New Hampshire | 1 | 2020 | 175 | 0.170 |
Why?
|
Receptors, Opioid, kappa | 1 | 2021 | 138 | 0.170 |
Why?
|
Checklist | 4 | 2018 | 827 | 0.170 |
Why?
|
Membrane Transport Proteins | 1 | 2005 | 1035 | 0.170 |
Why?
|
Child of Impaired Parents | 2 | 2006 | 460 | 0.160 |
Why?
|
1-Naphthylamine | 1 | 2019 | 49 | 0.160 |
Why?
|
Preventive Medicine | 1 | 2020 | 246 | 0.160 |
Why?
|
Receptors, Dopamine D4 | 2 | 2009 | 170 | 0.160 |
Why?
|
History, 20th Century | 2 | 2024 | 2767 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 14 | 2024 | 36426 | 0.150 |
Why?
|
Drug Therapy, Combination | 6 | 2018 | 6312 | 0.150 |
Why?
|
Least-Squares Analysis | 2 | 2009 | 369 | 0.150 |
Why?
|
Long-Term Care | 6 | 2008 | 633 | 0.150 |
Why?
|
Hippocampus | 2 | 2024 | 3766 | 0.150 |
Why?
|
Paternal Exposure | 1 | 2018 | 96 | 0.150 |
Why?
|
Writing | 1 | 2020 | 199 | 0.150 |
Why?
|
Follow-Up Studies | 24 | 2015 | 39106 | 0.150 |
Why?
|
History, 21st Century | 1 | 2024 | 1567 | 0.150 |
Why?
|
Personality Assessment | 7 | 2009 | 650 | 0.140 |
Why?
|
Family | 3 | 2011 | 3195 | 0.140 |
Why?
|
Opioid-Related Disorders | 2 | 2002 | 2164 | 0.140 |
Why?
|
Personality Inventory | 4 | 2007 | 1019 | 0.130 |
Why?
|
Blood Pressure | 8 | 2009 | 8481 | 0.130 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 2 | 2006 | 66 | 0.130 |
Why?
|
Parents | 3 | 2012 | 3563 | 0.130 |
Why?
|
Norepinephrine | 5 | 2021 | 897 | 0.130 |
Why?
|
Osteopontin | 2 | 2008 | 301 | 0.130 |
Why?
|
Reproducibility of Results | 15 | 2018 | 20100 | 0.130 |
Why?
|
Indans | 2 | 2006 | 92 | 0.120 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4243 | 0.120 |
Why?
|
Behavior, Animal | 2 | 2020 | 1878 | 0.120 |
Why?
|
Diagnostic Services | 1 | 2014 | 34 | 0.120 |
Why?
|
Universities | 1 | 2020 | 993 | 0.120 |
Why?
|
Aging | 5 | 2010 | 8710 | 0.120 |
Why?
|
Longitudinal Studies | 12 | 2015 | 14608 | 0.120 |
Why?
|
Prevalence | 12 | 2013 | 15733 | 0.120 |
Why?
|
Demography | 3 | 2013 | 1648 | 0.120 |
Why?
|
Membrane Glycoproteins | 1 | 2005 | 3701 | 0.120 |
Why?
|
Case-Control Studies | 17 | 2016 | 22176 | 0.120 |
Why?
|
Interpersonal Relations | 2 | 2020 | 1436 | 0.120 |
Why?
|
Conditioning, Classical | 1 | 2017 | 368 | 0.110 |
Why?
|
Single-Blind Method | 2 | 2010 | 1574 | 0.110 |
Why?
|
Attention | 2 | 2018 | 2396 | 0.110 |
Why?
|
Cerebrovascular Circulation | 1 | 2024 | 2727 | 0.110 |
Why?
|
Neurology | 1 | 2002 | 780 | 0.110 |
Why?
|
Self Concept | 1 | 2020 | 1045 | 0.110 |
Why?
|
Extinction, Psychological | 1 | 2017 | 371 | 0.110 |
Why?
|
Sex Characteristics | 2 | 2003 | 2639 | 0.110 |
Why?
|
Risperidone | 2 | 2006 | 381 | 0.110 |
Why?
|
Sex Factors | 9 | 2017 | 10554 | 0.110 |
Why?
|
Biomedical Research | 1 | 2009 | 3429 | 0.110 |
Why?
|
Brain Injuries | 2 | 2015 | 2054 | 0.110 |
Why?
|
3' Untranslated Regions | 2 | 2012 | 519 | 0.110 |
Why?
|
Cholinergic Agents | 2 | 2004 | 96 | 0.110 |
Why?
|
Quinolones | 2 | 2007 | 378 | 0.100 |
Why?
|
Affective Symptoms | 2 | 2006 | 417 | 0.100 |
Why?
|
Hydrocortisone | 1 | 2020 | 1819 | 0.100 |
Why?
|
Nicotinic Agonists | 4 | 2018 | 265 | 0.100 |
Why?
|
World Health Organization | 2 | 2017 | 1322 | 0.100 |
Why?
|
Nerve Tissue Proteins | 1 | 2005 | 4415 | 0.100 |
Why?
|
Risk Factors | 20 | 2020 | 74213 | 0.100 |
Why?
|
Piperazines | 3 | 2007 | 2523 | 0.100 |
Why?
|
Mothers | 2 | 2014 | 2198 | 0.090 |
Why?
|
Adaptation, Psychological | 2 | 2020 | 2629 | 0.090 |
Why?
|
Military Personnel | 1 | 2020 | 1246 | 0.090 |
Why?
|
Mice, Inbred C57BL | 9 | 2023 | 22174 | 0.090 |
Why?
|
Psychopathology | 2 | 2006 | 432 | 0.090 |
Why?
|
Remedial Teaching | 1 | 2010 | 16 | 0.090 |
Why?
|
Sexual Development | 1 | 2011 | 40 | 0.090 |
Why?
|
Heart Rate | 6 | 2009 | 4195 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1809 | 0.090 |
Why?
|
Clinical Trials as Topic | 4 | 2010 | 8002 | 0.090 |
Why?
|
London | 2 | 2021 | 234 | 0.090 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2010 | 27 | 0.090 |
Why?
|
Pregnancy | 13 | 2023 | 29890 | 0.090 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 2 | 2009 | 324 | 0.090 |
Why?
|
Time Factors | 11 | 2020 | 39969 | 0.090 |
Why?
|
Depression | 5 | 2023 | 8126 | 0.090 |
Why?
|
Sheep | 2 | 2009 | 1440 | 0.090 |
Why?
|
Horse Diseases | 1 | 2010 | 55 | 0.090 |
Why?
|
Receptors, Opioid, mu | 1 | 2011 | 167 | 0.090 |
Why?
|
West Nile Fever | 1 | 2010 | 75 | 0.090 |
Why?
|
Patient Dropouts | 3 | 2008 | 412 | 0.080 |
Why?
|
Self-Assessment | 2 | 2013 | 397 | 0.080 |
Why?
|
Time Perception | 1 | 2010 | 87 | 0.080 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2012 | 448 | 0.080 |
Why?
|
Body Mass Index | 4 | 2010 | 12953 | 0.080 |
Why?
|
Luteal Phase | 1 | 2009 | 138 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2630 | 0.080 |
Why?
|
Cerebellum | 4 | 2013 | 1501 | 0.080 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 413 | 0.080 |
Why?
|
Animals | 18 | 2023 | 168475 | 0.080 |
Why?
|
Child, Preschool | 8 | 2013 | 42232 | 0.080 |
Why?
|
Pregnancy Proteins | 1 | 2009 | 222 | 0.080 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 1972 | 0.080 |
Why?
|
Embryo Implantation | 2 | 2009 | 270 | 0.080 |
Why?
|
Antipsychotic Agents | 3 | 2007 | 3067 | 0.080 |
Why?
|
Drug Tolerance | 2 | 2007 | 367 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 6 | 2015 | 17904 | 0.080 |
Why?
|
Depressive Disorder, Major | 6 | 2014 | 4762 | 0.080 |
Why?
|
Hostility | 1 | 2009 | 183 | 0.080 |
Why?
|
Pemoline | 2 | 2005 | 18 | 0.080 |
Why?
|
Fear | 1 | 2017 | 1477 | 0.070 |
Why?
|
Occupations | 1 | 2010 | 515 | 0.070 |
Why?
|
Athletes | 1 | 2015 | 1137 | 0.070 |
Why?
|
Carbon Isotopes | 2 | 2006 | 458 | 0.070 |
Why?
|
Frontal Lobe | 3 | 2010 | 1420 | 0.070 |
Why?
|
Vital Signs | 1 | 2009 | 144 | 0.070 |
Why?
|
Irritable Mood | 2 | 2006 | 194 | 0.070 |
Why?
|
Drug Substitution | 1 | 2010 | 290 | 0.070 |
Why?
|
Adolescent Development | 1 | 2011 | 282 | 0.070 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.070 |
Why?
|
Brain Mapping | 7 | 2015 | 6635 | 0.070 |
Why?
|
Piperidines | 2 | 2006 | 1656 | 0.070 |
Why?
|
Progesterone | 2 | 2008 | 742 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2009 | 999 | 0.070 |
Why?
|
Attitude | 1 | 2012 | 775 | 0.070 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2012 | 895 | 0.070 |
Why?
|
Time | 2 | 2005 | 546 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2021 | 18255 | 0.060 |
Why?
|
Interferon Type I | 1 | 2009 | 562 | 0.060 |
Why?
|
Efficiency | 2 | 2007 | 476 | 0.060 |
Why?
|
Child Behavior | 1 | 2011 | 847 | 0.060 |
Why?
|
Social Class | 2 | 2014 | 2004 | 0.060 |
Why?
|
Self Psychology | 1 | 2005 | 8 | 0.060 |
Why?
|
Athletic Injuries | 1 | 2015 | 1216 | 0.060 |
Why?
|
Interview, Psychological | 2 | 2007 | 809 | 0.060 |
Why?
|
Spermatozoa | 2 | 2020 | 630 | 0.060 |
Why?
|
Problem Solving | 1 | 2008 | 443 | 0.060 |
Why?
|
Mother-Child Relations | 1 | 2009 | 495 | 0.060 |
Why?
|
Smoking | 4 | 2017 | 9053 | 0.060 |
Why?
|
Employee Performance Appraisal | 1 | 2005 | 86 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7391 | 0.060 |
Why?
|
Nootropic Agents | 1 | 2005 | 157 | 0.060 |
Why?
|
Mice | 11 | 2023 | 81539 | 0.060 |
Why?
|
Psychophysiologic Disorders | 1 | 2006 | 221 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2005 | 641 | 0.060 |
Why?
|
Antihypertensive Agents | 3 | 2006 | 2024 | 0.060 |
Why?
|
Cardiovascular System | 3 | 2006 | 834 | 0.060 |
Why?
|
In Situ Hybridization | 2 | 2006 | 1900 | 0.060 |
Why?
|
ROC Curve | 3 | 2020 | 3578 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 2 | 2006 | 2467 | 0.060 |
Why?
|
Analysis of Variance | 4 | 2017 | 6228 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2013 | 2421 | 0.050 |
Why?
|
Embryonic Development | 1 | 2008 | 721 | 0.050 |
Why?
|
Epithelium | 2 | 2006 | 1603 | 0.050 |
Why?
|
Tachycardia | 1 | 2005 | 600 | 0.050 |
Why?
|
Pediatrics | 2 | 2009 | 3589 | 0.050 |
Why?
|
Tics | 1 | 2004 | 74 | 0.050 |
Why?
|
Substance Abuse Detection | 1 | 2006 | 301 | 0.050 |
Why?
|
Personal Satisfaction | 1 | 2007 | 644 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5337 | 0.050 |
Why?
|
Cocaine-Related Disorders | 1 | 2006 | 461 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Wechsler Scales | 3 | 2014 | 257 | 0.050 |
Why?
|
Computer Systems | 1 | 2004 | 470 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Research Design | 3 | 2020 | 6180 | 0.050 |
Why?
|
Parietal Lobe | 1 | 2008 | 852 | 0.050 |
Why?
|
Behavior Therapy | 1 | 2008 | 879 | 0.050 |
Why?
|
Environment | 2 | 2014 | 1123 | 0.050 |
Why?
|
Dysthymic Disorder | 1 | 2002 | 75 | 0.050 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2004 | 459 | 0.050 |
Why?
|
Nerve Net | 1 | 2014 | 2291 | 0.050 |
Why?
|
Psychomotor Performance | 1 | 2010 | 1882 | 0.050 |
Why?
|
Secondary Prevention | 3 | 2021 | 1475 | 0.050 |
Why?
|
Antimanic Agents | 1 | 2005 | 520 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2019 | 10212 | 0.050 |
Why?
|
Health Status | 2 | 2006 | 4077 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5872 | 0.050 |
Why?
|
Mice, Inbred Strains | 1 | 2004 | 1762 | 0.050 |
Why?
|
Death, Sudden, Cardiac | 2 | 2006 | 1555 | 0.050 |
Why?
|
Menstruation | 1 | 2003 | 307 | 0.050 |
Why?
|
Psychotherapy | 1 | 2010 | 1647 | 0.050 |
Why?
|
Cognition | 3 | 2010 | 6992 | 0.050 |
Why?
|
Developmental Disabilities | 2 | 2010 | 1509 | 0.050 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2004 | 632 | 0.050 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2006 | 600 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 69 | 0.040 |
Why?
|
Behavior, Addictive | 1 | 2006 | 462 | 0.040 |
Why?
|
Prefrontal Cortex | 3 | 2011 | 2220 | 0.040 |
Why?
|
Thiazoles | 1 | 2007 | 1517 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2004 | 2264 | 0.040 |
Why?
|
Drinking Behavior | 1 | 2020 | 103 | 0.040 |
Why?
|
Mass Screening | 2 | 2007 | 5429 | 0.040 |
Why?
|
Age of Onset | 4 | 2008 | 3306 | 0.040 |
Why?
|
Diseases in Twins | 1 | 2002 | 446 | 0.040 |
Why?
|
Puberty | 1 | 2003 | 501 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2002 | 212 | 0.040 |
Why?
|
Anxiety | 3 | 2023 | 4573 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2226 | 0.040 |
Why?
|
State Medicine | 1 | 2021 | 216 | 0.040 |
Why?
|
Mental Processes | 1 | 2020 | 244 | 0.040 |
Why?
|
Crosses, Genetic | 1 | 2020 | 750 | 0.040 |
Why?
|
RNA, Messenger | 3 | 2018 | 12794 | 0.040 |
Why?
|
Capsules | 2 | 2009 | 191 | 0.040 |
Why?
|
Workplace | 1 | 2005 | 863 | 0.040 |
Why?
|
Prospective Studies | 12 | 2012 | 54423 | 0.040 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2006 | 1252 | 0.040 |
Why?
|
Stromal Cells | 1 | 2004 | 1330 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2019 | 117 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2004 | 12973 | 0.040 |
Why?
|
Affect | 2 | 2003 | 1486 | 0.040 |
Why?
|
Patient Selection | 1 | 2010 | 4244 | 0.040 |
Why?
|
Shock | 1 | 2020 | 314 | 0.040 |
Why?
|
Speech | 1 | 2023 | 554 | 0.040 |
Why?
|
Genotype | 5 | 2011 | 12990 | 0.040 |
Why?
|
Psychotropic Drugs | 1 | 2003 | 888 | 0.040 |
Why?
|
Observer Variation | 3 | 2011 | 2606 | 0.040 |
Why?
|
Motor Activity | 2 | 2020 | 2715 | 0.040 |
Why?
|
Hypertension | 3 | 2006 | 8540 | 0.040 |
Why?
|
Litter Size | 1 | 2017 | 49 | 0.040 |
Why?
|
Escape Reaction | 1 | 2017 | 57 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2927 | 0.030 |
Why?
|
Antisocial Personality Disorder | 2 | 2010 | 224 | 0.030 |
Why?
|
Sexual Behavior | 2 | 2018 | 2180 | 0.030 |
Why?
|
Regression Analysis | 2 | 2005 | 6345 | 0.030 |
Why?
|
Genomics | 1 | 2012 | 5821 | 0.030 |
Why?
|
Blotting, Western | 1 | 2004 | 5035 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2002 | 1380 | 0.030 |
Why?
|
Diagnostic Self Evaluation | 1 | 2018 | 224 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26129 | 0.030 |
Why?
|
Reference Values | 3 | 2010 | 4920 | 0.030 |
Why?
|
Evaluation Studies as Topic | 2 | 2009 | 1625 | 0.030 |
Why?
|
Receptors, Dopamine D2 | 1 | 2018 | 485 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8527 | 0.030 |
Why?
|
Mental Health | 1 | 2010 | 3250 | 0.030 |
Why?
|
Cerebral Cortex | 1 | 2012 | 5779 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3779 | 0.030 |
Why?
|
Drug Discovery | 1 | 2023 | 1051 | 0.030 |
Why?
|
Drinking | 1 | 2017 | 198 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
DNA Methylation | 2 | 2020 | 4399 | 0.030 |
Why?
|
Maze Learning | 1 | 2017 | 483 | 0.030 |
Why?
|
Employment | 2 | 2015 | 1118 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6075 | 0.030 |
Why?
|
Schools | 1 | 2003 | 1489 | 0.030 |
Why?
|
Clonidine | 2 | 2006 | 169 | 0.030 |
Why?
|
Fathers | 1 | 2017 | 376 | 0.030 |
Why?
|
Educational Status | 2 | 2015 | 2522 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2009 | 494 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2013 | 9001 | 0.030 |
Why?
|
Remission, Spontaneous | 1 | 2014 | 384 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2018 | 5790 | 0.030 |
Why?
|
Electrocardiography | 4 | 2009 | 6377 | 0.030 |
Why?
|
Prognosis | 2 | 2020 | 29629 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2010 | 15936 | 0.030 |
Why?
|
Risk Assessment | 1 | 2014 | 23996 | 0.030 |
Why?
|
Models, Neurological | 2 | 2012 | 1769 | 0.030 |
Why?
|
Intelligence Tests | 1 | 2014 | 503 | 0.030 |
Why?
|
United States | 7 | 2010 | 72340 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2004 | 3677 | 0.020 |
Why?
|
Models, Animal | 1 | 2018 | 2112 | 0.020 |
Why?
|
Macrophages | 1 | 2006 | 5767 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1881 | 0.020 |
Why?
|
Odds Ratio | 2 | 2019 | 9647 | 0.020 |
Why?
|
Reaction Time | 2 | 2008 | 2089 | 0.020 |
Why?
|
Massachusetts | 2 | 2015 | 8833 | 0.020 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 1388 | 0.020 |
Why?
|
Hospitals, General | 1 | 2015 | 798 | 0.020 |
Why?
|
Risk | 2 | 2016 | 9610 | 0.020 |
Why?
|
Weight Gain | 1 | 2021 | 2348 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2280 | 0.020 |
Why?
|
Outpatients | 2 | 2008 | 1597 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14665 | 0.020 |
Why?
|
Computer Simulation | 1 | 2023 | 6241 | 0.020 |
Why?
|
Infusion Pumps, Implantable | 1 | 2009 | 158 | 0.020 |
Why?
|
Hep G2 Cells | 1 | 2010 | 379 | 0.020 |
Why?
|
Smoking Cessation | 1 | 2021 | 2057 | 0.020 |
Why?
|
Sampling Studies | 1 | 2010 | 615 | 0.020 |
Why?
|
Boston | 1 | 2002 | 9327 | 0.020 |
Why?
|
Psychological Tests | 1 | 2011 | 640 | 0.020 |
Why?
|
Probability | 1 | 2014 | 2477 | 0.020 |
Why?
|
Biological Availability | 1 | 2009 | 390 | 0.020 |
Why?
|
Observation | 1 | 2010 | 310 | 0.020 |
Why?
|
Selection Bias | 1 | 2010 | 359 | 0.020 |
Why?
|
Intelligence | 1 | 1993 | 924 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2009 | 614 | 0.020 |
Why?
|
Luciferases | 1 | 2010 | 714 | 0.020 |
Why?
|
Israel | 1 | 2011 | 726 | 0.020 |
Why?
|
Self Disclosure | 1 | 2009 | 249 | 0.020 |
Why?
|
Social Behavior | 2 | 2006 | 1135 | 0.020 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2007 | 109 | 0.020 |
Why?
|
Interviews as Topic | 2 | 2005 | 2696 | 0.020 |
Why?
|
Achievement | 1 | 2009 | 288 | 0.020 |
Why?
|
Phenotype | 2 | 2020 | 16592 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2006 | 80647 | 0.020 |
Why?
|
Basal Ganglia | 1 | 2010 | 554 | 0.020 |
Why?
|
Oxygen | 2 | 2011 | 4227 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1250 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
Functional Laterality | 1 | 2013 | 2257 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3575 | 0.020 |
Why?
|
Systole | 1 | 2009 | 936 | 0.020 |
Why?
|
Estrous Cycle | 1 | 2006 | 65 | 0.020 |
Why?
|
Drug Interactions | 1 | 2011 | 1416 | 0.020 |
Why?
|
Georgia | 1 | 2007 | 185 | 0.020 |
Why?
|
Diastole | 1 | 2009 | 782 | 0.020 |
Why?
|
Phenethylamines | 1 | 2006 | 95 | 0.020 |
Why?
|
Interferons | 1 | 2010 | 706 | 0.020 |
Why?
|
Pregnancy in Adolescence | 1 | 2008 | 163 | 0.020 |
Why?
|
Postmortem Changes | 1 | 2006 | 119 | 0.020 |
Why?
|
Divorce | 1 | 2006 | 75 | 0.020 |
Why?
|
Socialization | 1 | 2006 | 87 | 0.020 |
Why?
|
Plasma | 1 | 2009 | 586 | 0.020 |
Why?
|
Tandem Repeat Sequences | 1 | 2006 | 180 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2010 | 857 | 0.020 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2006 | 303 | 0.020 |
Why?
|
Aged | 4 | 2018 | 169310 | 0.020 |
Why?
|
Autoradiography | 1 | 2006 | 728 | 0.020 |
Why?
|
Health Surveys | 2 | 2006 | 4061 | 0.020 |
Why?
|
Ovary | 1 | 2009 | 959 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1843 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3801 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2217 | 0.020 |
Why?
|
Xerostomia | 1 | 2005 | 94 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 2009 | 1998 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2006 | 784 | 0.010 |
Why?
|
Ovariectomy | 1 | 2006 | 614 | 0.010 |
Why?
|
Color Perception | 1 | 2005 | 213 | 0.010 |
Why?
|
Nausea | 1 | 2007 | 679 | 0.010 |
Why?
|
Unemployment | 1 | 2006 | 210 | 0.010 |
Why?
|
Clomipramine | 1 | 2003 | 54 | 0.010 |
Why?
|
Cattle | 1 | 2009 | 3849 | 0.010 |
Why?
|
Endometrium | 1 | 2006 | 403 | 0.010 |
Why?
|
Europe | 1 | 2011 | 3420 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
Task Performance and Analysis | 1 | 2008 | 763 | 0.010 |
Why?
|
Psychomotor Agitation | 1 | 2006 | 305 | 0.010 |
Why?
|
Safety | 1 | 2008 | 1149 | 0.010 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2005 | 578 | 0.010 |
Why?
|
Social Environment | 1 | 2008 | 1020 | 0.010 |
Why?
|
California | 1 | 2007 | 1430 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3606 | 0.010 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2003 | 107 | 0.010 |
Why?
|
Verbal Behavior | 1 | 2004 | 335 | 0.010 |
Why?
|
DNA Primers | 1 | 2006 | 2820 | 0.010 |
Why?
|
Calibration | 1 | 2005 | 818 | 0.010 |
Why?
|
Blood Pressure Determination | 1 | 2006 | 633 | 0.010 |
Why?
|
Movement Disorders | 1 | 2006 | 459 | 0.010 |
Why?
|
Heterozygote | 1 | 2008 | 2787 | 0.010 |
Why?
|
Drug Synergism | 1 | 2005 | 1757 | 0.010 |
Why?
|
Erectile Dysfunction | 1 | 2005 | 444 | 0.010 |
Why?
|
Managed Care Programs | 1 | 2007 | 940 | 0.010 |
Why?
|
Skin Diseases | 1 | 2009 | 1094 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2010 | 2095 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2006 | 2358 | 0.010 |
Why?
|
Estrogens | 1 | 2006 | 1522 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2006 | 2329 | 0.010 |
Why?
|
Fibroblasts | 1 | 2010 | 4142 | 0.010 |
Why?
|
Withholding Treatment | 1 | 2004 | 617 | 0.010 |
Why?
|
Wakefulness | 1 | 2006 | 1265 | 0.010 |
Why?
|
Urban Population | 1 | 2007 | 2036 | 0.010 |
Why?
|
Suicide, Attempted | 1 | 2008 | 1402 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 6484 | 0.010 |
Why?
|
Incidence | 2 | 2008 | 21355 | 0.010 |
Why?
|
Physician's Role | 1 | 2006 | 917 | 0.010 |
Why?
|
Protein Binding | 1 | 2011 | 9353 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2009 | 1667 | 0.010 |
Why?
|
Leukocytes | 1 | 2006 | 2026 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1638 | 0.010 |
Why?
|
Primary Health Care | 2 | 2006 | 4687 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14033 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6965 | 0.010 |
Why?
|
Placenta | 1 | 2006 | 1709 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2009 | 3060 | 0.010 |
Why?
|
Survival Analysis | 1 | 2009 | 10090 | 0.010 |
Why?
|
Headache | 1 | 2005 | 1256 | 0.010 |
Why?
|
Pedigree | 1 | 2004 | 4542 | 0.010 |
Why?
|
Data Collection | 1 | 2006 | 3322 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15266 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2003 | 2707 | 0.010 |
Why?
|
Schizophrenia | 1 | 2014 | 6937 | 0.010 |
Why?
|
Genetic Variation | 1 | 2010 | 6567 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12463 | 0.010 |
Why?
|
Child Development | 1 | 2006 | 2306 | 0.010 |
Why?
|
Underachievement | 1 | 1993 | 15 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 18966 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9469 | 0.010 |
Why?
|
Education, Special | 1 | 1993 | 86 | 0.010 |
Why?
|
Attitude to Health | 1 | 2002 | 2025 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5079 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2004 | 3688 | 0.010 |
Why?
|
Communication | 1 | 2006 | 3875 | 0.010 |
Why?
|
Recurrence | 1 | 2004 | 8466 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2005 | 7828 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2003 | 2492 | 0.010 |
Why?
|
Hospitalization | 1 | 2008 | 10721 | 0.000 |
Why?
|
Disease Progression | 1 | 2003 | 13510 | 0.000 |
Why?
|